Limited effects of an eIF2α S51A allele on neurological impairments in the 5xFAD mouse model of Alzheimer's disease

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Katharina Paesler - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Kan Xie - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Moritz M. Hettich - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Magdalena E. Siwek - , Federal Institute for Drugs and Medical Devices (BfArM) (Author)
  • Devon P. Ryan - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Susanne Schröder - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Anna Papazoglou - , Federal Institute for Drugs and Medical Devices (BfArM) (Author)
  • Karl Broich - , Federal Institute for Drugs and Medical Devices (BfArM) (Author)
  • Ralf Müller - , University of Cologne (Author)
  • Astrid Trog - , University of Bonn (Author)
  • Alexander Garthe - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Gerd Kempermann - , Chair of Genomics of Regeneration, Center for Regenerative Therapies Dresden, German Center for Neurodegenerative Diseases, Dresden site (Partner: DZNE of the Helmholtz Association) (Author)
  • Marco Weiergräber - , Federal Institute for Drugs and Medical Devices (BfArM) (Author)
  • Dan Ehninger - , German Center for Neurodegenerative Diseases (DZNE) (Author)

Abstract

Alzheimer's disease (AD) has been associated with increased phosphorylation of the translation initiation factor 2α (eIF2α) at serine 51. Increased phosphorylation of eIF2α alters translational control and may thereby have adverse effects on synaptic plasticity, learning, and memory. To analyze if increased levels of p-eIF2α indeed promote AD-related neurocognitive impairments, we crossed 5xFAD transgenic mice with an e I F 2 α S 51 A knock-in line that expresses the nonphosphorylatable eIF2α variant e I F 2 α S 51 A. Behavioral assessment of the resulting mice revealed motor and cognitive deficits in 5xFAD mice that were, with the possible exception of locomotor hyperactivity, not restored by the e I F 2 α S 51 A allele. Telemetric intracranial EEG recordings revealed no measurable effects of the e I F 2 α S 51 A allele on 5xFAD-associated epileptic activity. Microarray-based transcriptome analyses showed clear transcriptional alterations in 5xFAD hippocampus that were not corrected by the e I F 2 α S 51 A allele. In contrast to prior studies, our immunoblot analyses did not reveal increased levels of p-eIF2α in the hippocampus of 5xFAD mice, suggesting that elevated p-eIF2α levels are not a universal feature of AD models. Collectively, our data indicate that 5xFAD-related pathologies do not necessarily require hyperphosphorylation of eIF2α to emerge; they also show that heterozygosity for the nonphosphorylatable e I F 2 α S 51 A allele has limited effects on 5xFAD-related disease manifestations.

Details

Original languageEnglish
Article number825157
JournalNeural Plasticity
Volume2015
Publication statusPublished - 2015
Peer-reviewedYes

External IDs

Scopus 84927139023
PubMed 25883808
ORCID /0000-0002-5304-4061/work/142238826

Keywords

ASJC Scopus subject areas